FDA Expands Use of Antibody–Drug Conjugate to Additional Types of Lymphoma
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the antibody–drug conjugate brentuximab vedotin (Adcetris)...
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the antibody–drug conjugate brentuximab vedotin (Adcetris)...
Recently, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic vemurafenib (Zelboraf) for treating certain adults...
Last week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic acalabrutinib (Calquence) for treating adults...
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a revolutionary new type of immunotherapy...
Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the breast cancer community just...
Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which immunotherapeutics...
The flurry of treatments approved by the U.S. Food and Drug Administration (FDA) for treating hematological malignancies continued last...
This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel...
Yesterday marked a much anticipated milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced the...
This week, the U.S. Food and Drug Administration (FDA) added two new treatments to the armamentarium for hematologic oncologists...